Claims
- 1. A method of treating an individual suspected of suffering from a central nervous system disease or disorder comprising the step of:
implanting a sample from a culture of at least 95% pure, stable, homogeneous post-mitotic human neurons into said individual's brain.
- 2. The method of claim 1 wherein said neurons are differentiated NT2N cells.
- 3. The method of claim 1 wherein said neurons are transfected, differentiated NT2N cells that have been transfected with exogenous genetic material, wherein said transfected, differentiated cells express coding sequences of said exogenous genetic material to produce a protein product.
- 4. The method of claim 3 wherein said exogenous genetic material includes nucleic acid sequences that encode proteins selected from the group consisting of neurotransmitters and neurotrophic substances such as nerve growth factor, brain-derived neurotrophic factor (BDGF), basic fibroblast growth factor (bFGF) and glial-derived growth factor.
- 5. The method of claim 1 wherein said central nervous system disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke and nerve injuries.
- 6. A pharmaceutical composition comprising:
a sample from a culture of at least 95% pure, stable, homogeneous post-mitotic human neurons; and a pharmaceutically acceptable medium.
- 7. The pharmaceutical composition of claim 6 wherein said neurons are differentiated NT2N cells.
- 8. The pharmaceutical composition of claim 6 wherein said neurons are transfected, differentiated NT2N cells that have been transfected with exogenous genetic material; wherein transfected, differentiated cells express coding sequences of said exogenous genetic material to produce a protein product.
- 9. The pharmaceutical composition of claim 6 wherein said exogenous genetic material includes nucleic acid sequences that encode a protein selected from the group consisting of neurotransmitters (e.g., tyrosine hydroxlase) and neurotrophic substances such as nerve growth factor, brain-derived neurotrophic factor (BDGF), basic fibroblast growth factor (bFGF) and glial-derived growth factor.
- 10. A method of generating a non-human animal model for a central nervous system disease or disorder comprising the step of:
implanting a sample from a culture of at least 95% pure, stable, homogeneous post-mitotic human neurons into said non-human animal's brain.
- 11. The method of claim 10 wherein said neurons are NT2N cells.
- 12. The method of claim 10 wherein said neurons are NT2N cells that have been transfected with exogenous genetic material, wherein transfected cells express coding sequences of said exogenous genetic material to produce a protein product.
- 13. The method of claim 10 wherein said exogenous genetic material includes nucleic acid sequences that encode proteins selected from the group consisting of normal and mutated amyloid precursor, kinases, phosphotases, normal and mutated superoxidedismutase, neurofilament proteins and apolipoprotein 4.
- 14. The method of claim 10 wherein said disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke and nerve injuries.
- 15. The method of claim 10 wherein said animal is a rodent.
- 16. The method of claim 10 wherein said animal is an immunocompetent rodent and further comprising the step of administering Cyclosporin to said rodent before, during and/or after implanting said cells.
- 17. An non-human animal comprising:
a sample from a culture of at least 95% pure, stable, homogeneous post-mitotic human neurons implanted in the brain of said non-human animal.
- 18. The non-human animal of claim 17 wherein said neurons are NT2N cells.
- 19. The non-human animal of claim 17 wherein said neurons are NT2N cells that have been transfected with exogenous genetic material, wherein transfected cells express coding sequences of said exogenous genetic material to produce a protein product.
- 20. The non-human animal of claim 19 wherein said exogenous genetic material includes nucleic acid sequences that encode proteins selected from the group consisting of normal and mutated amyloid precursor, kinases, phosphotases, normal and mutated superoxidedismutase, neurofilament proteins and apolipoprotein 4.
- 21. A method of treating an individual suspected of suffering from an injury, disease or disorder characterized by nerve damage comprising the step of:
implanting a sample from a culture of at least 95% pure, stable, homogeneous post-mitotic human neurons at or near a sit of said nerve damage
- 22. The method of claim 21 wherein said neurons are differentiated NT2N cells.
- 23. The method of claim 21 wherein said injury is a spinal injury and said sample is implanted in said individual's spinal column.
- 24. The method of claim 1 wherein said injury is to a motor neuron.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US94/12899 |
Nov 1994 |
US |
|
Government Interests
[0001] This invention was made in the course of research sponsored by the NIH grant number NS18616. The United States Government has certain rights in this invention.